Arena moves PAH drug forward despite Phase Ib adverse event

Arena Pharmaceuticals is moving ahead with a Phase II clinical trial for its pulmonary arterial hypertension (PAH) drug APD811 based on data from two Phase I trials, including an incidence of transient atrial fibrillation that may have been caused by the company's oral prostacyclin (IP) receptor agonist.